Accumulation of HIV drug resistance mutations in patients failing first-line antiretroviral treatment in South Africa.

Patients failing antiretroviral treatment for extended periods of time are at risk of accumulating HIV drug resistance mutations (DRMs), which negatively influences second-line treatment. This retrospective study assessed the rate of DRM accumulation among South African patients with continued virological failure. Serial genotypic resistance testing was performed and DRMs were scored according to the 2009 IAS-USA list. Among 43 patients, 38 (88.4%) harbored ≥1 DRM. The median time between two sequential resistance tests was 5 months (IQR: 3-10). Thymidine analogue mutations accumulated at a rate of 0.07 mutation per month of drug exposure, which is faster than previously reported. Routine virological monitoring should be implemented in resource-limited settings to preserve susceptibility to second-line regimens.

[1]  J. Eron,et al.  Second‐line treatment in the Malawi antiretroviral programme: high early mortality, but good outcomes in survivors, despite extensive drug resistance at baseline * , 2010, HIV medicine.

[2]  D. Kuritzkes,et al.  Outcomes after virologic failure of first-line ART in South Africa , 2010, AIDS.

[3]  Ian Sanne,et al.  Varied Patterns of HIV-1 Drug Resistance on Failing First-Line Antiretroviral Therapy in South Africa , 2010, Journal of acquired immune deficiency syndromes.

[4]  A. Kamali,et al.  Affordable in-house antiretroviral drug resistance assay with good performance in non-subtype B HIV-1. , 2010, Journal of virological methods.

[5]  K. Ruxrungtham,et al.  Treatment outcomes and plasma level of ritonavir-boosted lopinavir monotherapy among HIV-infected patients who had NRTI and NNRTI failure , 2009, AIDS research and therapy.

[6]  R. Chaisson,et al.  Viremia, resuppression, and time to resistance in human immunodeficiency virus (HIV) subtype C during first-line antiretroviral therapy in South Africa. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  D. Richman,et al.  Update of the drug resistance mutations in HIV-1: December 2009. , 2009, Topics in HIV medicine : a publication of the International AIDS Society, USA.

[8]  B. Clotet,et al.  Rate of accumulation of thymidine analogue mutations in patients continuing to receive virologically failing regimens containing zidovudine or stavudine: implications for antiretroviral therapy programs in resource-limited settings. , 2009, The Journal of infectious diseases.

[9]  Sabine Yerly,et al.  Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. , 2009, The Lancet. Infectious diseases.

[10]  N. Parkin,et al.  The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy , 2009, AIDS.

[11]  C. Delaugerre,et al.  Protease Inhibitor Resistance Analysis in the MONARK Trial Comparing First-Line Lopinavir-Ritonavir Monotherapy to Lopinavir-Ritonavir plus Zidovudine and Lamivudine Triple Therapy , 2009, Antimicrobial Agents and Chemotherapy.

[12]  Elena Losina,et al.  HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programme , 2009, Antiviral therapy.

[13]  H. Gunthard,et al.  Update of the Drug Resistance Mutations in HIV-1. , 2008, Topics in HIV medicine : a publication of the International AIDS Society, USA.

[14]  D. Burton,et al.  The therapeutic phase I trial of the recombinant native HIV-1 Tat protein , 2008, AIDS.

[15]  B. Walker,et al.  Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  V. DeGruttola,et al.  The reverse transcriptase 67N 70R 215Y genotype is the predominant TAM pathway associated with virologic failure among HIV type 1C-infected adults treated with ZDV/ddI-containing HAART in southern Africa. , 2007, AIDS research and human retroviruses.

[17]  R. Chaisson,et al.  Adherence to Nonnucleoside Reverse Transcriptase InhibitorBased HIV Therapy and Virologic Outcomes , 2007, Annals of Internal Medicine.

[18]  S. Staszewski,et al.  Evolution of Resistance Mutations during Low-Level Viral Replication in HIV-1–Infected Patients Treated with Zidovudine/Lamivudine/Abacavir as a First-Line Regimen , 2007, Antiviral therapy.

[19]  Tulio de Oliveira,et al.  An automated genotyping system for analysis of HIV-1 and other microbial sequences , 2005, Bioinform..

[20]  Colombe Chappey,et al.  Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates. , 2003, The Journal of infectious diseases.

[21]  E. De Clercq,et al.  Prevalence and Characteristics of Multinucleoside-Resistant Human Immunodeficiency Virus Type 1 among European Patients Receiving Combinations of Nucleoside Analogues , 2000, Antimicrobial Agents and Chemotherapy.

[22]  R. Wood,et al.  Bmc Infectious Diseases Risk Factors for Poor Virological Outcome at 12 Months in a Workplace-based Antiretroviral Therapy Programme in South Africa: a Cohort Study , 2022 .